Diabetic cardiomyopathy (DCM) is an autonomous disease independent of concomitant micro and macrovascular disorders. DCM is one of the prominent causes of global morbidity and mortality and is in a rising trend with the increase in the prevalence of diabetes mellitus (DM). The increased prevalence of cardiometabolic disease observed over the last years raises an urgent and unmet need to research for novel mechanisms underlying cardiometabolic disease pathogenesis, prevention, diagnosis, and therapeutic intervention. DCM is characterized by early left ventricle diastolic dysfunction associated with the slow progression of cardiomyocyte hypertrophy leading to heart failure. Because unclear mechanisms involved in developing DCM are yet to be understood, no effective therapy is available in clinics.
Understanding the mechanisms involved in the development of Diabetic cardiomyopathy is challenging due to the involvement of multiple factors. Although hyperglycemia is the foremost etiological factor in the development of DCM, the molecular factors involved are altered metabolism, Renin-angiotensin signaling, mitochondrial dysfunction, oxidative stress, insulin resistance, inflammation, and extracellular matrix alone or in combination contributes to the progress of DCM. Therefore, understanding these factors in DCM development is of utmost importance to develop targeted therapies. Taking the leverage of recent advances in molecular, genetic and multi-omics techniques will help to understand critical pathways that contribute to DCM.
Specific themes we would like the contributors to address are as follows:
1) How renin-angiotensin-aldosterone system drives the pathological mechanisms in the development of DCM.
2) How mitochondria could be targeted in the treatment of DCM.
3) Role of oxidative stress and altered cardiac metabolism in the development of DCM.
4) Novel molecular factors as a potential target in DCM therapy.
5) Multi-omics approach in identifying new factors of DCM.
We will accept papers in the following formats: Original Research papers, Reviews, Methodology papers, and Systematic Reviews or meta-analyses.
Diabetic cardiomyopathy (DCM) is an autonomous disease independent of concomitant micro and macrovascular disorders. DCM is one of the prominent causes of global morbidity and mortality and is in a rising trend with the increase in the prevalence of diabetes mellitus (DM). The increased prevalence of cardiometabolic disease observed over the last years raises an urgent and unmet need to research for novel mechanisms underlying cardiometabolic disease pathogenesis, prevention, diagnosis, and therapeutic intervention. DCM is characterized by early left ventricle diastolic dysfunction associated with the slow progression of cardiomyocyte hypertrophy leading to heart failure. Because unclear mechanisms involved in developing DCM are yet to be understood, no effective therapy is available in clinics.
Understanding the mechanisms involved in the development of Diabetic cardiomyopathy is challenging due to the involvement of multiple factors. Although hyperglycemia is the foremost etiological factor in the development of DCM, the molecular factors involved are altered metabolism, Renin-angiotensin signaling, mitochondrial dysfunction, oxidative stress, insulin resistance, inflammation, and extracellular matrix alone or in combination contributes to the progress of DCM. Therefore, understanding these factors in DCM development is of utmost importance to develop targeted therapies. Taking the leverage of recent advances in molecular, genetic and multi-omics techniques will help to understand critical pathways that contribute to DCM.
Specific themes we would like the contributors to address are as follows:
1) How renin-angiotensin-aldosterone system drives the pathological mechanisms in the development of DCM.
2) How mitochondria could be targeted in the treatment of DCM.
3) Role of oxidative stress and altered cardiac metabolism in the development of DCM.
4) Novel molecular factors as a potential target in DCM therapy.
5) Multi-omics approach in identifying new factors of DCM.
We will accept papers in the following formats: Original Research papers, Reviews, Methodology papers, and Systematic Reviews or meta-analyses.
